| 生物活性 | SRX3305 is a BTK/PI3K/BRD4 inhibitor with IC50 values of 6.5 nM, 15 nM, and 4 nM for BTK, PI3Kα, and PI3Kδ, respectively; it inhibits the proliferation of and promotes apoptosis in chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) cells in a dose-dependent manner, exerts potent antitumor effects without harming healthy cells, inhibits activation-induced proliferation of primary CLL cells in vitro and effectively blocks microenvironment-mediated survival signals, also inhibits the migration of CLL cells toward CXCL-12 and CXCL-13, retains its antitumor activity in Ibrutinib (MS-M40234)-resistant CLL cells, and can be used for research on CLL, diffuse large B-cell lymphoma (DLBCL), and MCL. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| IC50 & Target | PI3Kα:15 nM | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 体外研究 (In Vitro) |
SRX3305 (0.1-100 μM;72 小时) 可抑制 B-NHL 细胞系的增殖,平均 IC50 值为 1.38 µM。 Cell Proliferation Assay
Apoptosis Analysis
Western Blot Analysis
Western Blot Analysis
Cell Proliferation Assay
Western Blot Analysis
Cell Cytotoxicity Assay
Cell Viability Assay
Cell Migration Assay
Cell Proliferation Assay
Western Blot Analysis
Cell Viability Assay
Cell Viability Assay
Cell Viability Assay
Cell Viability Assay
Cell Viability Assay
|